Meta-analysis revealed that APS combination therapy significantly downregulated PD-1/PD-L1 expression in tumor tissues (SMD = −3.66, 95% CI [-6.11, −1.20], p = 0.003; Figure 10). This evidence concerns the gene PDCD1 and neoplasm.